BeiGene

BeiGene

Yahoo Finance • yesterday

Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth

(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth, who has served as Chairman of Kymera sinc... Full story

Yahoo Finance • 4 days ago

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made... Full story

Yahoo Finance • 6 days ago

BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA

BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approv... Full story

Yahoo Finance • last month

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatment Three oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline SAN CARLOS, Calif., May 21, 2026--(BUSINESS WIRE)--BeOn... Full story

Yahoo Finance • last month

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • last month

Patient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 Shares

What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Patient Square Capital LP disclosed the purchase of 210,000 shares of Nektar Therapeutics(NASDAQ:NKTR). The estimated value of the trade was... Full story

Yahoo Finance • last month

BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma

BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. BEQALZI is a foundational BCL2 inhibitor designed for greater potency and selectivity, with potenti... Full story

Yahoo Finance • 2 months ago

Did FDA Fast-Track HER2 Regimen Just Shift BeOne Medicines' (ONC) Investment Narrative?

On 29 April 2026, BeOne Medicines announced that the FDA granted Priority Review to an sBLA for TEVIMBRA with ZIIHERA and chemotherapy, alongside Breakthrough Therapy Designation for ZIIHERA-based regimens in first-line treatment of unrese... Full story

Yahoo Finance • 2 months ago

Here are the major earnings after the close Wednesday

Major earnings expected after the bell on Wednesday include: * SL Green Realty Corp. (SLG [https://seekingalpha.com/symbol/SLG]) * J.B. Hunt Transport Services (JBHT [https://seekingalpha.com/symbol/JBHT]) * BeOne Medicines AG (ONC... Full story

Yahoo Finance • 2 months ago

BeiGene Q1 2026 Earnings Preview

* BeiGene (ONC [https://seekingalpha.com/symbol/ONC]) is scheduled to announce Q1 earnings results on Wednesday, April 15th, after market close. * The consensus EPS Estimate is $0.85 [https://seekingalpha.com/symbol/ONC/earnings/estima... Full story

Yahoo Finance • 3 months ago

BeOne wins China approval for Amgen’s lung cancer drug Imdelltra

[Approved stamp on application form or business agreement document] * BeOne Medicines (ONC [https://seekingalpha.com/symbol/ONC]) announced on Friday that Chinese officials granted conditional approval for tarlatamab, a bispecific T-cel... Full story

Yahoo Finance • 3 months ago

BeOne Medicines price target lowered to $411 from $412 at Truist

Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech. Reactivity to regulatory and policy shifts across... Full story

Yahoo Finance • 3 months ago

Wolfe Research Initiates Coverage of BeOne Medicines AG (ONC) with Outperform Rating

BeOne Medicines AG (NASDAQ:ONC) is one of the 7 Fastest Growing European Stocks to Invest In. On March 26, 2026, Wolfe Research analyst Kalpit Patel initiated coverage on BeOne Medicines AG (NASDAQ:ONC) with an Outperform rating and a $34... Full story

Yahoo Finance • 3 months ago

This Fintech Stock Is Up 21% in a Year as Profits Surge, but One Fund's Nearly $300 Million Sale Cut Its Stake in Half

On February 17, 2026, HHLR Advisors reported selling 1,607,930 shares of Futu Holdings(NASDAQ:FUTU), an estimated $276.00 million transaction based on quarterly average pricing. What happened According to a Securities and Exchange Commis... Full story

Yahoo Finance • 4 months ago

BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment

BeOne Medicines AG (NASDAQ:ONC) is among the 12 best stocks to buy and hold for the next 2 years. On February 26, BeOne Medicines AG (NASDAQ:ONC) reported total global revenues of $1.5 billion for the fourth quarter of 2025 and $5.3 billi... Full story

Yahoo Finance • 4 months ago

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quart... Full story

Yahoo Finance • 4 months ago

HHLR Advisors Fully Exits Baidu as AI Push Tests Its Advertising-Funded Model

Key Points HHLR Advisors, Ltd sold 1,641,000 shares of Baidu; estimated trade size was $216.23 million based on average pricing for the quarter Quarter-end position value declined by $216.23 million, reflecting both the share sale and cha... Full story

Yahoo Finance • 6 months ago

Strong Momentum Lifted BeOne Medicines AG (ONC) in Q3

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its third-quarter 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. A copy of the letter c... Full story

Yahoo Finance • 7 months ago

A Fresh Look at BeOne Medicines (ONC) Valuation as Shares Gain Momentum

BeOne Medicines (ONC) shares saw a modest 2% bump in the latest trading session. Investors have been keeping an eye on the company's progress, especially given its ongoing focus on innovative cancer therapies and recent leadership moves.... Full story

Yahoo Finance • 7 months ago

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the Inflation Reduction Act. Continue Reading View Comments... Full story